Voretigene neparvovec (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Voretigene neparvovec" in English language version.

refsWebsite

Global rank English rank

4nih.gov

4^th place

3web.archive.org

1^st place

2tga.gov.au

3,984^th place

2,622^nd place

2fda.gov

447^th place

338^th place

2doi.org

2^nd place

2statnews.com

8,771^st place

5,253^rd place

1canada.ca

1,712^th place

1,063^rd place

1hres.ca

low place

1europa.eu

68^th place

117^th place

1sparktx.com

low place

1washingtonpost.com

34^th place

27^th place

1ctvnews.ca

768^th place

482^nd place

1swissmedic.ch

low place

1npr.org

92^nd place

72^nd place

1scientificamerican.com

896^th place

674^th place

1philly.com

664^th place

398^th place

1springer.com

274^th place

309^th place

1medscape.com

719^th place

636^th place

1semanticscholar.org

11^th place

8^th place

1bloomberg.com

99^th place

77^th place

1fiercepharma.com

low place

8,921^st place

1cnbc.com

220^th place

155^th place

bloomberg.com

"Landmark Therapy to Treat Blindness Gets One Step Closer to FDA Approval". Bloomberg.com. 12 October 2017. Retrieved 12 October 2017.

canada.ca

health-products.canada.ca

"Luxturna Product information". Health Canada. 25 April 2012. Retrieved 21 October 2020.

cnbc.com

Tirrell M (3 January 2018). "A US drugmaker offers to cure rare blindness for $850,000". CNBC. Retrieved 3 January 2018.

ctvnews.ca

"'I never saw stars before': Gene therapy brings back 8-year-old Canadian boy's sight". CTVNews. 14 October 2020. Archived from the original on 20 October 2020. Retrieved 21 October 2020.

doi.org

Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. (August 2017). "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial". Lancet. 390 (10097): 849–860. doi:10.1016/S0140-6736(17)31868-8. PMC 5726391. PMID 28712537.
Lee H, Lotery A (August 2017). "Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3". Lancet. 390 (10097): 823–824. doi:10.1016/S0140-6736(17)31622-7. PMID 28712536. S2CID 26983863.

europa.eu

ema.europa.eu

"Luxturna EPAR". European Medicines Agency (EMA). 24 September 2018. Retrieved 21 October 2020.

fda.gov

"Luxturna". U.S. Food and Drug Administration (FDA). 19 December 2017. Archived from the original on 15 December 2019. Retrieved 2 April 2020.
"FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss". U.S. Food and Drug Administration (FDA). 24 March 2020. Archived from the original on 26 May 2019. Retrieved 28 November 2022.

fiercepharma.com

"Spark grabs FDA nod for Luxturna, a breakthrough gene therapy likely bearing a pioneering price". FiercePharma. 19 December 2017.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Luxturna". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medscape.com

Lewis R (13 October 2017). "FDA Panel Backs Gene Therapy for Inherited Blindness". Medscape.

nih.gov

pubmed.ncbi.nlm.nih.gov

Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. (August 2017). "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial". Lancet. 390 (10097): 849–860. doi:10.1016/S0140-6736(17)31868-8. PMC 5726391. PMID 28712537.
Lee H, Lotery A (August 2017). "Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3". Lancet. 390 (10097): 823–824. doi:10.1016/S0140-6736(17)31622-7. PMID 28712536. S2CID 26983863.

dailymed.nlm.nih.gov

"Luxturna- voretigene neparvovec-rzyl kit". DailyMed. 4 December 2019. Retrieved 14 August 2020.

ncbi.nlm.nih.gov

Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. (August 2017). "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial". Lancet. 390 (10097): 849–860. doi:10.1016/S0140-6736(17)31868-8. PMC 5726391. PMID 28712537.

npr.org

"First Gene Therapy For Inherited Disease Gets FDA Approval". NPR. 19 December 2017.

philly.com

"FDA approves Spark's gene therapy for rare blindness pioneered at CHOP". Philly. Retrieved 24 March 2018.

scientificamerican.com

Clarke T. "Gene Therapy for Blindness Appears Initially Effective, Says U.S. FDA". Scientific American. Retrieved 12 October 2017.

semanticscholar.org

api.semanticscholar.org

Lee H, Lotery A (August 2017). "Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3". Lancet. 390 (10097): 823–824. doi:10.1016/S0140-6736(17)31622-7. PMID 28712536. S2CID 26983863.

sparktx.com

ir.sparktx.com

"Press Release - Investors & Media - Spark Therapeutics". Ir.sparktx.com. Retrieved 9 October 2017.^{[permanent dead link]}

springer.com

adisinsight.springer.com

"Voretigene neparvovec - Spark Therapeutics - AdisInsight". adisinsight.springer.com.

statnews.com

"Spark's gene therapy for blindness is racing to a historic date with the FDA". Statnews.com. 9 October 2017. Retrieved 9 October 2017.
"The anxious launch of Luxturna, a gene therapy with a record sticker price". STAT. 21 March 2018. Retrieved 24 March 2018.

swissmedic.ch

"Luxturna (active substance: voretigene neparvovec)". Swissmedic. Retrieved 14 January 2025.

tga.gov.au

"Luxturna Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 13 August 2020. Retrieved 16 August 2020.
"Luxturna". Therapeutic Goods Administration (TGA). 13 August 2020. Retrieved 22 September 2020.

washingtonpost.com

McGinley L (19 December 2017). "FDA approves first gene therapy for an inherited disease". Washington Post.

web.archive.org

"Luxturna". U.S. Food and Drug Administration (FDA). 19 December 2017. Archived from the original on 15 December 2019. Retrieved 2 April 2020.
"FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss". U.S. Food and Drug Administration (FDA). 24 March 2020. Archived from the original on 26 May 2019. Retrieved 28 November 2022.
"'I never saw stars before': Gene therapy brings back 8-year-old Canadian boy's sight". CTVNews. 14 October 2020. Archived from the original on 20 October 2020. Retrieved 21 October 2020.